For the second quarter ending June 30 2023, SI-BONE ($NASDAQ:SIBN) reported total revenue of $33.3 million – a 30.2% year-over-year increase. Net income for the same quarter was -$11.2 million, a significant improvement compared to the previous year’s loss of -$18.5 million. The fiscal year 2023 second quarter results were released on August 7 2023.
Analysis – Si-bone Stock Fair Value
GoodWhale has conducted a thorough analysis of SI-BONE‘s wellbeing. Using our proprietary Valuation Line, we have determined that SI-BONE’s fair value is around $24.7. At the time of writing, SI-BONE stock is being traded at $23.4 – despite its true value being 5.4% greater than the current price. This suggests that SI-BONE is being undervalued at the moment and may provide a good investment opportunity for those considering buying in. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Si-bone. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Si-bone. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Si-bone. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Si-bone are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Its competitors are Heart Tronics Inc, ClearPoint Neuro Inc, Vycor Medical Inc.
Heart Tronics Inc is a medical device company that manufactures and sells cardiac pacemakers and other implantable cardioverter defibrillator devices. As of 2022, the company had a market capitalization of 15.68k and a return on equity of 110.55%. The company’s products are used to treat heart rhythm disorders and are implanted in the chest.
– ClearPoint Neuro Inc ($NASDAQ:CLPT)
ClearPoint Neuro Inc, a medical device company, focuses on developing and commercializing technologies to treat neurological disorders. The company offers NeuroBlate System, a laser ablation system that is used to treat various brain disorders; and ClearVec, a cannula system that is used to deliver drugs or other substances to specific areas of the brain. It has a market cap of 229.59M as of 2022 and a Return on Equity of -23.99%.
Vycor Medical Inc is a medical device company that develops, manufactures, and markets minimally invasive products to treat neurological conditions. The company has a market cap of 3.24M as of 2022 and a Return on Equity of 8.79%. Vycor Medical’s products are used by neurosurgeons, neurologists, and other physicians to treat conditions such as brain tumors, cerebral aneurysms, and stroke.
SI-BONE reported an impressive 30.2% year-over-year increase in total revenue for the second quarter of FY2023, reaching USD 33.3 million. This was accompanied by a net income of -11.2 million, significantly narrowed from its -18.5 million loss from the corresponding period in the previous year. This strong performance suggests that SI-BONE is recovering from its earlier financial woes and is now on a path of growth and recovery, making it an attractive investment opportunity.